Hematopoietic Stem Cell Transplantation-related Indications

Top drugs studied for this disease

All Approvals Safety alerts Label changes Trial results Research Guidance Withdrawals

EMA withdrawal · 2020-02-14
EMA Withdrawn: Zalmoxis (allogeneic T cells genetically modified with a retroviral vector encoding for a truncated form of the human low affinity nerve growth factor receptor (ΔLNGFR) and the herpes simplex I virus thymidine kinase (HSV-TK Mut2)) — MolMed SpA
The EMA withdrew Zalmoxis, a gene-modified allogeneic T cell product for hematopoietic stem cell transplantation and graft-versus-host disea…